Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share

Early report Major update Updated Mar 6, 2026, 11:15 PM UTC

Track this event Edit in app More event pages

What changed

Early report surfaced from GlobeNewswire Mergers and Acquisitions 4h ago.

First seen Mar 6, 2026, 11:15 PM UTC Latest source Mar 6, 2026, 11:15 PM UTC

Update 1 4h ago

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

GlobeNewswire Mergers and Acquisitions •published Mar 6, 2026, 11:15 PM UTC •fetched Mar 6, 2026, 11:35 PM UTC

Event stats

Reports 1

Sources 1

Confidence low

Score 41

Entity focus

LisataTherapeuticsEntersDefinitiveAgreement

Source spread

GlobeNewswire Mergers and Acquisitions

Turn this into an alert

Draft the watch from the event wording, then let PushMe handle follow-up changes.

Notify me about major new developments on Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc., especially involving Lisata, Therapeutics, Enters.

Create alert from this event